RxDoctor Payments Data

Amanda Davenport, NP

Family · Fort Oglethorpe, GANPI 1174018857

Payments from drug & device makers

$5,739in general payments, 2019–2025

Across 163 payments — averaging $35.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$934
  • Novartis$471
  • AstraZeneca$448
  • Daiichi Sankyo Inc.$271
  • Gilead$201
  • Amgen$199
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,54097%
  • Other$1993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,739 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$243,457
Medicare patients
96
Services billed
13,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$24,206
XareltoRivaroxaban15$18,816
Exemestane11$2,362
Anastrozole96$1,937
Potassium Chloride91$1,478
Hydroxyurea21$867
Letrozole41$850
Levothyroxine Sodium26$835
Tamoxifen Citrate26$634
Ondansetron OdtOndansetron33$560
Gabapentin39$416
Prochlorperazine Maleate23$366
Levofloxacin31$334
Albuterol Sulfate HfaAlbuterol Sulfate13$314
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$24,20624 claims
Johnson & JohnsonXarelto$179$18,81615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Fort Oglethorpe

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →